Hannover: 9. Bronchiektasen-Weltkonferenz

Mittwoch, 24. - Samstag, 27. Juni 2026

Motto: 10 Jahre Fortschritt – von einer vernachlässigten Krankheit zu einer globalen Bewegung

Aus dem Programm

Autoimmunity in bronchiectasis

Airway Inflammation: experimental insights from recent clinical trials

Mucus pathophysiology (and what it means for bronchiectasis)

Beyond the bug: bacterial virulence, interactions and resistance

Redesigning bronchiectasis care in the digital era: continuous monitoring, AI and the future of personalized medicine

Ätiologische Diagnostik - was ist möglich, wie viel ist nötig?

Bronchiektasen in Deutschland: Sichtbakriet erhöhen, Versorgung verbessern

Imprinting of microbial tolerance in the airways by immune memory

Common mechanisms across respiratory diseases that could be leveraged in bronchiectasis

Novel insights into airway dysbiosis and chronic infection

Restoring near-normal F508del-CFTR function: a cell-permeable nanobody synergizes with CFTR modulators in primary airway epithelial cells from patients with cystic fi brosis

Novel therapeutic targets in bronchiectasis

Multi-omics investigations of Host-Pathogen Interface. Insight in bronchiectasis

An exploratory sputum DNA methylation analysis in patients with bronchiectasis

Paediatric bronchiectasis: unique mechanisms, modifiable risks and lifelong care continuum

What patients would like to say to their care team and what patients would like their care team to talk with them about

Evidence-based treatment in the era of bronchiectasis - comparing recent CHEST and ERS Guidelines

Global bronchiectasis or lost in translation?

My interpretation of the DPP1 inhibition data in bronchiectasis

What is Disease progression?

Preventing progression: what evidence do we have?

Efficacy and safety of Itepekimab in patients with non-cystic fibrosis bronchiectasis

An italian, multicenter, pragmatic, randomized, controlled trial assessing the efficacy and safety of nocturnal humidification therapy in patients with bronchiectasis: the AIRVO-BX study

Phase 3b ENCORE study of amikacin liposome inhalation suspension in new occurrence of Mycobacterium avium complex lung infection

Ort: HCC – Hannover Congress Centrum, Theodor-Heuss-Platz 1-3, 30175 Hannover